BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2006

View Archived Issues

Sustained quality of life gains seen with rotigotine in restless legs syndrome

Read More

Investigational anticonvulsant increases high-voltage sleep

Read More

Series B financing to support preclinical efforts at GlycoMimetics

Read More

Phase III breast cancer study of tesmilifene cleared to continue

Read More

Nilotinib safe in imatinib-resistant leukemia patients in phase I study

Read More

Epoetin delta evaluated in patients with chronic kidney disease

Read More

Cloretazine active in elderly acute myeloid leukemia patients

Read More

Studies of NRP-104 pharmacokinetics, abuse potential reported

Read More

YM-393059: a novel dual inhibitor of PDE7A and PDE4 for inflammatory disorders

Read More

At 5 years, papillomavirus vaccine Gardasil found to induce immune memory

Read More

Phase III program for Gabitril in GAD fails to meet endpoints

Read More

PMA filed for OP-1 Putty in posterolateral lumbar spine fusion surgeries

Read More

Series B financing at Tengion

Read More

Wythe and VeroScience sign agreement for Cycloset

Read More

ATLAS trial results show adalimumab effects in ankylosing spondylitis

Read More

MK-0812 not effective in rheumatoid arthritis

Read More

Efficacy of certolizumab pegol independent of C-reactive protein in Crohn's disease

Read More

Pfizer patents novel nicotinic acetylcholine receptor modulators for promoting smoking cessation

Read More

Recent patents report new therapeutic agents for metabolic disorders

Read More

Recent patents report new anticoagulants for thrombotic disorders

Read More

Nastech and Amylin sign development agreement for exenatide nasal spray

Read More

Metabolex and Ortho-McNeil enter metabolic disease strategic agreement

Read More

Schering AG terminates Alprox-TD license with NexMed

Read More

Affymax and Takeda sign agreement for Hematide

Read More

Valera seeks to begin clinical studies of VP-004 naltrexone implant

Read More

End of phase II meeting for Anturol

Read More

CF-102 begins nonclinical development

Read More

Macugen studied in phase IV maintenance trial

Read More

Celacade shows efficacy in NYHA Class II chronic heart failure patients

Read More

European approval for Tysabri in MS

Read More

Sprycel approved for two new indications

Read More

Approvable letter for Lybrel oral contraceptive

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing